The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.

The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.

This invention concerns the treatment of HER-2 positive breast cancer cells by mediating the signal of GRB7 using an anti-HER-1 antibody, such as panitumumab.

This invention concerns the treatment of HER-2 positive breast cancer cells by mediating the signal of GRB7 using an anti-HER-1 antibody, such as panitumumab.

This invention concerns the treatment of HER-2 positive breast cancer cells by mediating the signal of GRB7 using an anti-HER-1 antibody, such as panitumumab.

The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.

The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.

The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.

Embodiments of the disclosure include methods and compositions related to treating an individual for HER2+ positive cancer with an appropriate treatment based on outcome of a multiparameter classifier. The methods allow for identification of HER2+ individuals that are suitable to avoid chemotherapy, in specific embodiments. Methods of the disclosure also allow for identification of HER2+ individuals that should not avoid chemotherapy. In specific embodiments, the multiparameter classifier identifies whether there is (1) a ratio of HER2 amplification, relative to a control probe, of greater than or equal to 4.5; (2) a HER2 expression level score of 3+, as determined by immunohistochemistry, in at least 90% of breast cancer cells; (3) whether there is a HER2-enriched molecular subtype; and (4) whether the individual has a wildtype PIKC3A gene.

Embodiments of the disclosure include methods and compositions related to treating an individual for HER2+ positive cancer with an appropriate treatment based on outcome of a multiparameter classifier. The methods allow for identification of HER2+ individuals that are suitable to avoid chemotherapy, in specific embodiments. Methods of the disclosure also allow for identification of HER2+ individuals that should not avoid chemotherapy. In specific embodiments, the multiparameter classifier identifies whether there is (1) a ratio of HER2 amplification, relative to a control probe, of greater than or equal to 4.5; (2) a HER2 expression level score of 3+, as determined by immunohistochemistry, in at least 90% of breast cancer cells; (3) whether there is a HER2-enriched molecular subtype; and (4) whether the individual has a wildtype PIKC3A gene.